Web Stats Provided By Google Analytics

Thursday, February 20, 2014

Exelixis' Q4 Loss Widens as Investors Await Key Trial Data

For the quarter, Exelixis reported net product revenue from the sale of Cometriq, its only FDA-approved product to treat metastatic medullary thyroid cancer, of $4.3 million.

http://ift.tt/1dTIgP3

No comments:

Post a Comment

Popular Healthcare Law Roundup Posts